CryoPort Beats Guidance, Charts Path to Profitability on Cell and Gene Therapy Momentum
In a sign of accelerating momentum for advanced medical treatments, CryoPort Systems, Inc. (NASDAQ: CYRX) closed its fiscal 2025 with revenue surpassing its own projections, fueled by the expanding commercial rollout of cell and gene therapies. The temperature-controlled logistics specialist reported annual revenue from continuing operations of $176.2 million, topping the high end of its prior guidance.
The fourth quarter saw double-digit growth, a trend management directly attributes to the scaling of commercial therapies. Revenue from supporting these commercial treatments surged 29% year-over-year to a record $33.4 million, accounting for 20% of total revenue in Q4. Clinical trial revenue, the company's traditional backbone, also grew a healthy 14% to $47.1 million.
"We are not just participating in this industry; we are increasingly integral to its commercial success," said CEO Jerrell Shelton during the earnings call. The numbers back the claim: CryoPort ended the year supporting a record 760 clinical trials and 20 commercial therapies globally, representing approximately 70% of all cell and gene therapy trials.
The near-term pipeline appears robust. Shelton highlighted an expected 13 new Biologics License or Marketing Authorization Applications and nine new therapy approvals in 2026, with three customer approvals anticipated as soon as March or April. He described the clinical portfolio as "spring-loaded," with 86 Phase 3 and 361 Phase 2 trials currently supported.
Beyond top-line growth, CryoPort is making strides toward profitability. Cost initiatives helped drive gross margin to 47%, with adjusted EBITDA improving by $12 million. The company formally targets positive adjusted EBITDA in the second half of 2026. CFO Robert Stefanovich emphasized this goal will be met through "growth and operational efficiencies," not just cost-cutting, pointing to strategic expansions like a new global supply chain center in Paris and a rapid build-out in Belgium for a key commercial client.
Strategic partnerships remain a cornerstone of the growth strategy. The completed sale of CRYOPDP to DHL provided a capital infusion and is expected to bolster CryoPort's reach in Asia-Pacific and EMEA regions. Collaborations with Cardinal Health and Parexel aim to create a complementary ecosystem for therapy developers, handling everything from reimbursement support to clinical trial design.
Looking ahead, CryoPort issued fiscal 2026 revenue guidance of $190 million to $194 million, which Shelton called an "appropriate starting point" given macroeconomic uncertainty, while acknowledging potential upside. The company reported a solid start to Q1 with minimal disruption from global logistics challenges.
Industry Voices React
Dr. Anya Sharma, Biotech Supply Chain Analyst: "CryoPort's results validate the critical, and often underappreciated, role of logistics in the cell and gene therapy revolution. Their growing commercial revenue mix is a leading indicator of the industry's maturation. The path to profitability seems credible, tied directly to therapy approvals."
Michael Reeves, Portfolio Manager at Horizon Capital: "The beat on guidance is encouraging, but the market wants to see that adjusted EBITDA turn positive. The 2026 target is clear, and their 'spring-loaded' pipeline provides the potential catalyst. Execution on their facility expansions will be key to supporting the next wave of approvals."
Lisa Chen, Editor at 'The Pharma Skeptic' Blog: "Let's not get carried away. They're still burning cash and their 'profitability' is an adjusted, future metric. The DHL partnership is a wild card—integrating with a giant can stifle innovation. This is a bet on the entire CGT sector not hitting a development wall, which is far from guaranteed."
David Park, Former Clinical Trial Logistics Manager: "Having been in the trenches, CryoPort's scale is becoming a real moat. Supporting 70% of trials means they have unparalleled data and network effects. Their move into bioservices and sterile kitting is smart—it locks in clients for the long haul."